ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

NuvaRing Lawsuits

Merck & Co. agreed in 2014 to settle all claims over its hormone-infused NuvaRing birth control implant. Plaintiffs in nearly 2,000 lawsuits alleged serious injuries and deaths from blood clots, heart attacks and strokes.

World-class athlete Megan Henry started using NuvaRing birth control 10 days before she found herself gasping for air on the side of a mountain in 2012. At the time, she didn’t know that NuvaRing had caused her to develop dangerous blood clots. She later joined others who sued NuvaRing’s maker, Merck & Co., alleging the device caused life-threatening injuries.

A member of the U.S. Army’s elite Soldier-Athlete Program, Henry was training for the 2014 Winter Olympics in the skeleton – a bare-bones sled that screams down slopes at 80 mph—when she found herself battling a sudden shortness of breath.

“It was like an elephant was sitting on my chest all the time,” she told CNN.

It didn’t get better. She visited six doctors who told her it was asthma or stress or the effects of breathing the thin mountain air. Finally, a pulmonologist ordered a CAT scan. It showed multiple pulmonary embolisms, or blood clots blocking her lungs.

Rushed to the hospital, the aspiring Olympian was put on a breathing machine. She was told her athletic career was over, and if she had not been in the peak physical condition required of a world-class athlete, she likely would have died.

As a result of her injuries, Henry will face a higher risk of recurring pulmonary embolisms for the rest of her life. She can never take hormonal treatments, including birth control, again. If she gets pregnant, she will have to take anticoagulant medicine to prevent blood clots.

Henry’s experience in 2012 had already been repeated with hundreds of other women since at least 2005. Studies have found the progestin used in NuvaRing can increase the risk of a blood clot called venous thromboembolism (VTE) by as much as 6.5 times.

One type of VTE known as deep vein thrombosis (DVT) occurs when a blood clot forms in the body’s large veins. Pulmonary embolism (PE) can happen if a DVT breaks loose, travels to the lungs and stops blood flow. This can be fatal.

In October 2013, Merck & Co. Inc., added a warning about an increased risk of blood clots to the contraceptive’s label. By that time, hundreds of lawsuits were piling up against Merck subsidiary Organon BioSciences.

NuvaRing Litigation Timeline:
  • August 2008
    The first 11 of 1,983 eventual lawsuits were combined in a federal multidistrict litigation (MDL).
  • March 2009
    A total of 215 state lawsuits were consolidated into a multicounty litigation (MCL) in New Jersey.
  • February 2014
    Merck agreed to a $100 million settlement to resolve all remaining lawsuits and claims not yet filed.
  • June 2014
    The settlement was finalized.
  • July 2014
    The time period for claimants to opt-in to the settlement ended.
  • April 2019
    The U.S. Judicial Panel on Multidistrict Litigation reported 89 cases were still pending.

Lawsuits Point to Blood Clots, Heart Attacks, Strokes and Deaths

As NuvaRing users experienced VTEs, there were mounting questions about whether the contraceptive’s manufacturers should have known about the risk and warned women about it.

Following a rising tide of deaths and serious injuries from VTEs, heart attacks and strokes, women or their surviving family members began filing lawsuits against the manufacturers. Their stories were often similar: healthy women who used NuvaRing and suffered severe medical complications or death.

Janis Mitchell-McGuire, for example, started using the birth control in 2004. Then 28, she suffered a PE just six months later, had to be hospitalized twice, and was prescribed anticoagulation medications to prevent further clotting. She filed a lawsuit against Merck in 2008.

LaMonica Green was 17 years old when she started using NuvaRing in 2009. Within weeks, she suffered a PE and died. Her mother filed a wrongful death lawsuit.

Dana Jenn, a long-distance runner with no history of blood clots, suffered a sudden shortness of breath and collapsed on a treadmill during a workout in 2005. Hours later, the 40-year-old would die of a PE. Sarah Jenn, Dana’s daughter, filed a lawsuit in 2007.

“This lawsuit wasn’t about punishing anyone or any kind of personal gain. I thought it was important to add her voice to all the other women who had a bad outcome from this drug.”

Source: Jenn’s daughter, Sarah, told the St. Louis Post-Dispatch in 2014

In all, women or their families filed more than 2,100 lawsuits in state and federal courts. They alleged the manufacturer failed to adequately test etonogestrel — the progestin hormone in NuvaRing. They also claimed the company based safety information on oral contraceptive studies alone.

FDA Raises Safety Questions Before Approving NuvaRing

The U.S. Food and Drug Administration had questioned the safety of NuvaRing prior to approving it in 2001. A review said the increased risk of VTE was “the most controversial safety issue.” The risk was compared to oral contraceptives using similar hormones as NuvaRing.

“There remains considerable concern in the literature over an increased risk of VTE events with desogestrel-containing oral contraceptives,” Dr. Daniel Davis, the medical officer who authored the report for the FDA, wrote in 2001. “With approval of this product, the label should clearly reflect the safety concern about an increased risk of VTE.”

The FDA decided the warning was not necessary when it granted approval for NuvaRing later that year. NuvaRing’s label did not include a warning about VTE and cardiovascular risks until October 2013.

By that time, several other studies had shown increased risks for potentially fatal blood clots, heart attack and strokes for NuvaRing users compared to other combination hormone contraceptives (CHCs) such as birth control pills and patches.

Merck Settles Claims for $100 Million

In February 2014, Merck & Co. agreed to settle all claims against the company for $100 million. The settlement was finalized in June 2014. Roughly 3,800 people were eligible for a portion of the settlement – including those who filed lawsuits and those whose claims had not been filed in court.

To be eligible to enroll in the settlement, claimants had to have alleged an injury due to NuvaRing prior to Feb. 7, 2014. Eligible plaintiffs then had to submit a notice of intent to opt-in form and a completed claim package before deadlines set by the court in Missouri.

The final deadline to enroll was extended to July 21, 2014. The claim package had to include documentation of injuries, a patient’s NuvaRing prescription records and an authorization to release medical records and other information.

Some Opt Out of Settlement

Not all the claimants opted into the settlement. Among those who chose not to take part in the settlement were the parents of Erika Langhart.

Langhart collapsed with severe chest pains and suffered two heart attacks as paramedics worked to get her to a hospital. She died on Thanksgiving Day in 2011 from a pulmonary embolism.

“Shame on them,” Langhart’s father, Rick, told the Durango Herald in Colorado in 2014. “This settlement agreement, orchestrated by Merck and the attorneys on both sides, driven by their own greed, has all but eliminated the chance for Merck to be taken to trial.”

In opting out of the settlement, Rick and Karen Langhart chose instead to pursue a separate trial over their daughter’s death. But a San Francisco court dismissed their case on Sept. 10, 2016.

Ericka Langhart was a recent graduate of American University in Washington, D.C. when she died. She and Megan Henry were friends. Henry discussed the Merck settlement with Salt Lake City television station KSTU in 2015.

“People who lost their daughters or wives, the compensation [was] $74,000, which may sound like it’s a lot of money but not for someone’s life,” Henry said.

NuvaRing Legal Facts
  1. Number of Lawsuits 1,996
  2. Plaintiff Injuries Cardiovascular injuries, blood clots, pulmonary embolisms, death
  3. Defendants Organon USA., Inc., N.V. Organon Schering Corp., Merck & Co., Inc., Merck Sharp & Dohme, Corp.
  4. Top Settlement $100 million settlement with 3,800 claimants in 2014
  5. Lawsuits Still Pending 86

Please seek the advice of a medical professional before making health care decisions.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Medically Reviewed By
Dr. Joseph Palermo
Dr. Joseph Palermo Osteopathic Medicine

23 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Doyle, J. (2014, March 1). FDA approved NuvaRing despite experts' safety concerns. Retrieved from
  2. KForce at the English language Wikipedia [GFDL ( or CC-BY-SA-3.0 (], via Wikimedia Commons. Retrieved from
  3. Kaye, R. and Shepherd, S. (2015, April 7). Families, Lawsuits, Raise Questions about NuvaRing. Retrieved from
  4. Karlsson, J. and Brenner, M. (2014, January). Danger in the Ring. Retrieved from
  5. FDA. (2013, October). NuvaRing Label. Retrieved from
  6. Moylan, T. (2014, February 7). Merck Settles All NuvaRing Birth Control Injury Cases for $100 Million. Retrieved from
  7. Supreme Court of New Jersey. (2009, March 10). Supreme Court Order. Retrieved from
  8. USA Today. (2014, June 5). NuvaRing Case Finalized in $100M Settlement. Retrieved from
  9. Lidegaard, Ø., et al. (2012, May 10). Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-up Study, Denmark 2001-10. Retrieved from
  10. Merck & Co. (n.d.). Annual Reports & Proxy. Retrieved from
  11. FDA. (2011). Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints (pg. 6-7). Retrieved from
  12. Lidegaard, Ø., et al. (2012, June 14). Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception. Retrieved from
  13. FDA. (2000, October 6). Center for Drug Evaluation and Research; Application Number 21-187; Medical Review (pt. 1) (pg. 1). Retrieved from
  14. FDA. (2000, October 6). Center for Drug Evaluation and Research; Application Number 21-187; Medical Review (pt. 2) (pg. 58). Retrieved from
  15. Howell v. Organon USA, Inc., et. al. (2012, August 31).
  16. U.S. Judicial Panel on Multidistrict Litigation. (2008, August 22). In Re: NuvaRing Products Liability Litigation; Transfer Order. Retrieved from
  17. Doyle, J. (2014, March 1). FDA Approved NuvaRing Despite Experts’ Safety Concerns. Retrieved from
  18. U.S. Dist. Ct., Eastern Dist. of Missouri. (2014, February 7). In Re: NuvaRing Products Liability Litigation; Order Regarding Settlement Agreement Deadlines. Retrieved from
  19. Olivarius-Mcallister, C. (2014, February 17). Parents Turn Down $100M Settlement. Retrieved from
  20. Feeley, J. and Voreacos, D. (2014, February 8). Merck to Pay $100 Million NuvaRing Pact If Women Join. Retrieved from
  21. Butler, A. and Benjamin, S. (2016, January 13). Karen Langhart Sends Nearly 40 Packages to Friends Before Taking Her Own Life. Retrieved from
  22. Figueroa, C. (2015, April 7). Olympic Athlete Warns Against Using the NuvaRing. Retrieved from
  23. U.S. Judicial Panel on Multidistrict Litigation. (2019, April 15). MDL Statistics Report - Distribution of Pending MDL Dockets by District. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617